Moderna (NASDAQ: MRNA) Q1 2026 Earnings: Revenue Beat and Strategic Pipeline Expansion

Font: Financial Modeling Prep  • May 01, 2026

• Moderna reported a smaller-than-expected quarterly loss of $3.40 per share and significantly surpassed revenue estimates with $389 million, primarily driven by international COVID-19 vaccine sales.
• The biotechnology firm is strategically expanding its focus beyond COVID-19, developing new mRNA therapeutics for infectious diseases like the flu and various types of cancer through its robust drug pipeline.
• Despite a negative price-to-earnings (P/E) ratio of -6.31 indicating unprofitability over the last year, Moderna maintains strong short-term financial health with a current ratio of 3.29 and projects up to 10% revenue growth for 2026.

Moderna (NASDAQ: MRNA) is a biotechnology company specializing in messenger RNA (mRNA) therapeutics. It gained global recognition for its COVID-19 vaccine. The company is now expanding its focus to develop treatments for other infectious diseases, such as the flu, and various types of cancer through its drug pipeline.

On May 1, 2026, Moderna reported a quarterly loss of $3.40 per share, which was better than the analyst consensus estimate of a $3.96 loss. The total GAAP net loss was $1.3 billion. As highlighted by Access Newswire, this figure includes a significant one-time, non-recurring litigation settlement charge of $900 million.

The company also announced revenue of $389 million for the quarter, surpassing the consensus estimate of $236.36 million. This strong revenue performance was driven by international sales of its COVID-19 vaccine. According to its financial results, international markets accounted for approximately 80% of this total revenue.

Despite the revenue beat, Moderna's financial metrics show it was not profitable over the last year, with a negative price-to-earnings (P/E) ratio of -6.31. A P/E ratio compares a company's stock price to its earnings per share. A negative ratio indicates the company had a net loss during the period.

However, the company maintains good short-term financial health with a strong current ratio of 3.29, suggesting it has ample assets to cover its short-term liabilities. Looking ahead, Moderna reaffirmed its plan to deliver up to 10% revenue growth and reduce operating expenses for the year 2026.